The pharmaceutical industry has been divided in recent months by the question of whether mega-mergers are the way forward, the UK Financial Times reports.
The recent economic crisis has led to a burst of M&A activity, with Pfizer acquiring Wyeth for $68.0 billion, USA-based Merck & Co buying Schering-Plough in a $41.1-billion reverse takeover and Swiss drug major Roche taking full control of its US affiliate Genentech in a $46.8-billion deal (Marketletters passim).
Can big pharma become too big?
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze